World Workshop on Oral Medicine VI

A systematic review of the treatment of mucocutaneous pemphigus vulgaris

R. McMillan, J. Taylor, M. Shephard, R. Ahmed, M. Carrozzo, J. Setterfield, S. Grando, M. Mignogna, M. Kuten-Shorrer, T. Musbah, A. Elia, R. McGowan, A. R. Kerr, M. S. Greenberg, T. Hodgson, David Sirois

Research output: Contribution to journalArticle

Abstract

Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.

Original languageEnglish (US)
Pages (from-to)132-142e61
JournalOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume120
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Oral Medicine
Pemphigus
Controlled Clinical Trials
Education
Randomized Controlled Trials
Observational Studies
Mycophenolic Acid
Biological Therapy
Intravenous Immunoglobulins
Azathioprine
Therapeutics
Fluorescent Antibody Technique
Adrenal Cortex Hormones
Outcome Assessment (Health Care)
Guidelines
Safety
Mortality
Research

ASJC Scopus subject areas

  • Surgery
  • Oral Surgery
  • Pathology and Forensic Medicine
  • Radiology Nuclear Medicine and imaging
  • Dentistry (miscellaneous)

Cite this

World Workshop on Oral Medicine VI : A systematic review of the treatment of mucocutaneous pemphigus vulgaris. / McMillan, R.; Taylor, J.; Shephard, M.; Ahmed, R.; Carrozzo, M.; Setterfield, J.; Grando, S.; Mignogna, M.; Kuten-Shorrer, M.; Musbah, T.; Elia, A.; McGowan, R.; Kerr, A. R.; Greenberg, M. S.; Hodgson, T.; Sirois, David.

In: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Vol. 120, No. 2, 2015, p. 132-142e61.

Research output: Contribution to journalArticle

McMillan, R, Taylor, J, Shephard, M, Ahmed, R, Carrozzo, M, Setterfield, J, Grando, S, Mignogna, M, Kuten-Shorrer, M, Musbah, T, Elia, A, McGowan, R, Kerr, AR, Greenberg, MS, Hodgson, T & Sirois, D 2015, 'World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris', Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 120, no. 2, pp. 132-142e61. https://doi.org/10.1016/j.oooo.2015.01.022
McMillan, R. ; Taylor, J. ; Shephard, M. ; Ahmed, R. ; Carrozzo, M. ; Setterfield, J. ; Grando, S. ; Mignogna, M. ; Kuten-Shorrer, M. ; Musbah, T. ; Elia, A. ; McGowan, R. ; Kerr, A. R. ; Greenberg, M. S. ; Hodgson, T. ; Sirois, David. / World Workshop on Oral Medicine VI : A systematic review of the treatment of mucocutaneous pemphigus vulgaris. In: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2015 ; Vol. 120, No. 2. pp. 132-142e61.
@article{d8e0bb5ec85b46f3912b5a034d65a9d8,
title = "World Workshop on Oral Medicine VI: A systematic review of the treatment of mucocutaneous pemphigus vulgaris",
abstract = "Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8{\%} (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.",
author = "R. McMillan and J. Taylor and M. Shephard and R. Ahmed and M. Carrozzo and J. Setterfield and S. Grando and M. Mignogna and M. Kuten-Shorrer and T. Musbah and A. Elia and R. McGowan and Kerr, {A. R.} and Greenberg, {M. S.} and T. Hodgson and David Sirois",
year = "2015",
doi = "10.1016/j.oooo.2015.01.022",
language = "English (US)",
volume = "120",
pages = "132--142e61",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - World Workshop on Oral Medicine VI

T2 - A systematic review of the treatment of mucocutaneous pemphigus vulgaris

AU - McMillan, R.

AU - Taylor, J.

AU - Shephard, M.

AU - Ahmed, R.

AU - Carrozzo, M.

AU - Setterfield, J.

AU - Grando, S.

AU - Mignogna, M.

AU - Kuten-Shorrer, M.

AU - Musbah, T.

AU - Elia, A.

AU - McGowan, R.

AU - Kerr, A. R.

AU - Greenberg, M. S.

AU - Hodgson, T.

AU - Sirois, David

PY - 2015

Y1 - 2015

N2 - Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.

AB - Objective To determine the efficacy and safety of interventions for pemphigus vulgaris (PV). Study Design We conducted a systematic review from 2003 to 2013 according to the Cochrane Collaboration methodology. Randomized controlled trials (RCTs) or controlled clinical trials (CCTs) and observational studies were conducted along with diagnosis confirmed by clinical, histopathologic, and immunofluorescence criteria. Primary outcomes were disease remission and mortality; several relevant secondary outcomes were also included. Results Fourteen RCTs or CCTs and 110 observational studies were included in the final analyses. RCTs or CCTs demonstrated considerable heterogeneity in outcome measures, and all had a high risk of bias for at least 1 of 8 domains. Of the studies, 96.8% (120) described the use of oral corticosteroids. Azathioprine and mycophenolate-mofetil were the most commonly cited treatments. An increasing number of studies described biologic therapies (rituximab, intravenous immunoglobulin [IVIg]). Evidence supporting recent comprehensive treatment guidelines was reviewed. Conclusions We found persisting wide variations in treatment practice and inadequate quality of research supporting optimal PV treatment.

UR - http://www.scopus.com/inward/record.url?scp=84947041333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947041333&partnerID=8YFLogxK

U2 - 10.1016/j.oooo.2015.01.022

DO - 10.1016/j.oooo.2015.01.022

M3 - Article

VL - 120

SP - 132-142e61

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 2

ER -